All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
ADX-2191 granted orphan drug designation by the EMA for the treatment of primary LBCL of immune-privileged sites
On August 28, 2025, the European Medicines Agency granted orphan drug designation to ADX-2191, a sterile, non-compounded intravitreal formulation of methotrexate, for the treatment of patients with primary large B-cell lymphoma of immune-privileged sites including primary vitreoretinal lymphoma, for which there are currently no approved therapies in the European Union.1 ADX-2191 was previously granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of patients with primary vitreoretinal lymphoma.1
A proposed clinical trial will assess cancer cell clearance after 30 days of therapy in up to 20 patients following 1:1 randomization to receive either one or eight intraocular injections of ADX-2191. The trial is expected to begin in the second half of 2025.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, does lisocabtagene maraleucel offer a durable, potentially curative remission with a one-time infusion in second-line large B-cell lymphoma?